FDA Review Of Ipsen’s Dysport Set Back Three Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requests a risk communication plan for the cervical dystonia drug candidate.
You may also be interested in...
Ipsen’s Dysport Gets Complete Response Letter, Request For REMS
Complete response letter issued to Ipsen, requesting a final REMS, label and safety update report for the botulinum toxin product.
Ipsen’s Dysport Gets Complete Response Letter, Request For REMS
Complete response letter issued to Ipsen, requesting a final REMS, label and safety update report for the botulinum toxin product.
Lilly Prasugrel Review Extended: Why No News May Be Good News
Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.